Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/15/2024 | $19.00 → $25.00 | In-line → Outperform | Evercore ISI |
| 7/10/2024 | $19.00 | Outperform | Raymond James |
| 5/6/2024 | $16.00 → $18.00 | Equal-Weight → Overweight | Morgan Stanley |
| 1/4/2024 | $19.00 → $17.00 | Outperform → In-line | Evercore ISI |
| 12/12/2023 | $16.00 | Hold | Stifel |
| 10/3/2023 | $20.00 | Outperform | Evercore ISI |
| 5/30/2023 | $20.00 | Equal-Weight | Morgan Stanley |
| 3/9/2023 | Hold | Needham |
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collected a total of 94,119,275 units*, or 569,743 pounds, of used contact lenses, eye care and lens care materials in the United States. That's equivalent to the weight of roughly 690 polar bears1. "Our unique recycling programs continue to be popular with environmentally conscious eye care professionals, patients and consumers," said Amy Butler, vice president, Global Environment, Health, Safety, and Sustainability, Bausch + Lomb. "The collective success of the
Revenue of $1.196 Billion GAAP Net Income Attributable to Bausch + Lomb Corporation of $4 Million Adjusted EBITDA (non-GAAP)1 of $212 Million; Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $227 Million Revenue Grew 19% as Reported and 19% on a Constant Currency1 Basis Compared to the Third Quarter of 2023, Driven by Solid Execution and Growth Across All Segments Raising Full-Year 2024 Revenue Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2024 financial results. "Our focus on execution continues to drive growth, with significant opportunity
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ full range of vision intraocular lens (IOL), which offers a continuous range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform. "We're confident that U.S. surgeons will agree with what their Canadian colleagues have already told us: enVista Envy delivers exceptional outcomes and meets cataract patients' high expectations, as well as their own," said Anthony Wallace, vice president and general manager, U.S. Surgical, Bausch + Lomb. A mu
Evercore ISI upgraded Bausch + Lomb from In-line to Outperform and set a new price target of $25.00 from $19.00 previously
Raymond James initiated coverage of Bausch + Lomb with a rating of Outperform and set a new price target of $19.00
Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $18.00 from $16.00 previously
SC 13G - Bausch & Lomb Corp (0001860742) (Subject)
Shares of General Dynamics Corporation (NYSE:GD) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter EPS results. Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from Benzinga Pro. General Dynamics shares declined 5.2% to $279.26 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers NuZee, Inc. (NASDAQ:NUZE) jumped 192% to $3.01. Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 142.4% to $3.0799 after falling over 22% on Tuesday. Selina Hospitality PLC
Raymond James analyst Gary Nachman initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Outperform rating and announces Price Target of $19.
Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and raises the price target from $15 to $15.5.
4/A - Bausch & Lomb Corp (0001860742) (Issuer)
4/A - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai
Mr. Bailey and Mr. Stewart Will Join Bausch + Lomb on April 24, 2023 Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023. Both Mr. Bailey and Mr. Stewart will join the executive management team of the Company. Concurrent with these appointments, Christina Ackermann will step down from her role as EVP, General Counsel and president, Ophthalmic Pharmaceuticals, and will leave Bausch + Lomb on April
Revenue of $1.196 Billion GAAP Net Income Attributable to Bausch + Lomb Corporation of $4 Million Adjusted EBITDA (non-GAAP)1 of $212 Million; Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $227 Million Revenue Grew 19% as Reported and 19% on a Constant Currency1 Basis Compared to the Third Quarter of 2023, Driven by Solid Execution and Growth Across All Segments Raising Full-Year 2024 Revenue Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2024 financial results. "Our focus on execution continues to drive growth, with significant opportunity
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, October 30, 2024 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/49633 Participant Event Dial-in: +1 (888) 506-0062 (North A
Revenue of $1.216 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $151 Million Adjusted EBITDA (non-GAAP)1 of $209 Million Revenue Grew 17% as Reported and 20% on a Constant Currency1 Basis Compared to the Second Quarter of 2023, Driven by Broad-Based Growth Across All Business Segments Raising Full-Year 2024 Revenue and Adjusted EBITDA (non-GAAP)1 Guidance Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2024 financial results. "Our continued growth is being fueled by a relentless focus on selling and operational excellence, and a commitmen
8-K - Bausch & Lomb Corp (0001860742) (Filer)
10-Q - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)